Physostigmine ameliorates the delusions of Alzheimer's disease
Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a doubleblind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acet...
Gespeichert in:
| Veröffentlicht in: | Biological psychiatry (1969) 1993-04, Vol.33 (7), p.536-541 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 541 |
|---|---|
| container_issue | 7 |
| container_start_page | 536 |
| container_title | Biological psychiatry (1969) |
| container_volume | 33 |
| creator | Cummings, Jeffrey L. Gorman, David G. Shapira, Jill |
| description | Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a doubleblind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms. |
| doi_str_mv | 10.1016/0006-3223(93)90009-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75783532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0006322393900093</els_id><sourcerecordid>75783532</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-4cc73cbe73691d299ae49471c0a8aacf72681bab8fc478681b3ab2763a9a04ce3</originalsourceid><addsrcrecordid>eNp9kEtLxEAMgAdRdH38A4UexMehOq92OhdBxBcIetDzkE5Td6QPnXQF_fW27LJHIZCEfAnhY-xQ8AvBRX7JOc9TJaU6s-rcjp1N1QabicKoVGouN9lsjeywXaKPsTVSim22XWRCcWVn7Opl_kM9DeG9DR0m0GIT-ggDUjLMMamwWVDoO0r6OrlufucYWoynlFSBEAj32VYNDeHBKu-xt7vb15uH9On5_vHm-in1WmRDqr03ypdoVG5FJa0F1FYb4TkUAL42Mi9ECWVRe22KqVZQSpMrsMC1R7XHTpZ3P2P_tUAaXBvIY9NAh_2CnMlMoTIlR1AvQR97ooi1-4yhhfjjBHeTNjc5cZMTZ8eYtDk1rh2t7i_KFqv10srTOD9ezYE8NHWEzgdaY9roLFd6xK6WGI4uvgNGRz5g57EKEf3gqj78_8cfNy2IcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75783532</pqid></control><display><type>article</type><title>Physostigmine ameliorates the delusions of Alzheimer's disease</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Cummings, Jeffrey L. ; Gorman, David G. ; Shapira, Jill</creator><creatorcontrib>Cummings, Jeffrey L. ; Gorman, David G. ; Shapira, Jill</creatorcontrib><description>Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a doubleblind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms.</description><identifier>ISSN: 0006-3223</identifier><identifier>EISSN: 1873-2402</identifier><identifier>DOI: 10.1016/0006-3223(93)90009-3</identifier><identifier>PMID: 8513039</identifier><identifier>CODEN: BIPCBF</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>acetylcholine ; acetylcholinesterase ; acetylcholinesterase inhibitor ; Aged ; Alzheimer Disease - drug therapy ; Alzheimer Disease - physiopathology ; Alzheimer Disease - psychology ; Alzheimer's disease ; Biological and medical sciences ; delusions ; Delusions - drug therapy ; Delusions - physiopathology ; Delusions - psychology ; Hallucinations - drug therapy ; Hallucinations - physiopathology ; Hallucinations - psychology ; haloperidol ; Humans ; Male ; Medical sciences ; Miscellaneous ; Neuropharmacology ; Pharmacology. Drug treatments ; physostigmine ; Physostigmine - therapeutic use ; Receptors, Cholinergic - drug effects ; Receptors, Cholinergic - physiology</subject><ispartof>Biological psychiatry (1969), 1993-04, Vol.33 (7), p.536-541</ispartof><rights>1993</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-4cc73cbe73691d299ae49471c0a8aacf72681bab8fc478681b3ab2763a9a04ce3</citedby><cites>FETCH-LOGICAL-c415t-4cc73cbe73691d299ae49471c0a8aacf72681bab8fc478681b3ab2763a9a04ce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0006-3223(93)90009-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4745634$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8513039$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cummings, Jeffrey L.</creatorcontrib><creatorcontrib>Gorman, David G.</creatorcontrib><creatorcontrib>Shapira, Jill</creatorcontrib><title>Physostigmine ameliorates the delusions of Alzheimer's disease</title><title>Biological psychiatry (1969)</title><addtitle>Biol Psychiatry</addtitle><description>Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a doubleblind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms.</description><subject>acetylcholine</subject><subject>acetylcholinesterase</subject><subject>acetylcholinesterase inhibitor</subject><subject>Aged</subject><subject>Alzheimer Disease - drug therapy</subject><subject>Alzheimer Disease - physiopathology</subject><subject>Alzheimer Disease - psychology</subject><subject>Alzheimer's disease</subject><subject>Biological and medical sciences</subject><subject>delusions</subject><subject>Delusions - drug therapy</subject><subject>Delusions - physiopathology</subject><subject>Delusions - psychology</subject><subject>Hallucinations - drug therapy</subject><subject>Hallucinations - physiopathology</subject><subject>Hallucinations - psychology</subject><subject>haloperidol</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>physostigmine</subject><subject>Physostigmine - therapeutic use</subject><subject>Receptors, Cholinergic - drug effects</subject><subject>Receptors, Cholinergic - physiology</subject><issn>0006-3223</issn><issn>1873-2402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEtLxEAMgAdRdH38A4UexMehOq92OhdBxBcIetDzkE5Td6QPnXQF_fW27LJHIZCEfAnhY-xQ8AvBRX7JOc9TJaU6s-rcjp1N1QabicKoVGouN9lsjeywXaKPsTVSim22XWRCcWVn7Opl_kM9DeG9DR0m0GIT-ggDUjLMMamwWVDoO0r6OrlufucYWoynlFSBEAj32VYNDeHBKu-xt7vb15uH9On5_vHm-in1WmRDqr03ypdoVG5FJa0F1FYb4TkUAL42Mi9ECWVRe22KqVZQSpMrsMC1R7XHTpZ3P2P_tUAaXBvIY9NAh_2CnMlMoTIlR1AvQR97ooi1-4yhhfjjBHeTNjc5cZMTZ8eYtDk1rh2t7i_KFqv10srTOD9ezYE8NHWEzgdaY9roLFd6xK6WGI4uvgNGRz5g57EKEf3gqj78_8cfNy2IcA</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>Cummings, Jeffrey L.</creator><creator>Gorman, David G.</creator><creator>Shapira, Jill</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930401</creationdate><title>Physostigmine ameliorates the delusions of Alzheimer's disease</title><author>Cummings, Jeffrey L. ; Gorman, David G. ; Shapira, Jill</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-4cc73cbe73691d299ae49471c0a8aacf72681bab8fc478681b3ab2763a9a04ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>acetylcholine</topic><topic>acetylcholinesterase</topic><topic>acetylcholinesterase inhibitor</topic><topic>Aged</topic><topic>Alzheimer Disease - drug therapy</topic><topic>Alzheimer Disease - physiopathology</topic><topic>Alzheimer Disease - psychology</topic><topic>Alzheimer's disease</topic><topic>Biological and medical sciences</topic><topic>delusions</topic><topic>Delusions - drug therapy</topic><topic>Delusions - physiopathology</topic><topic>Delusions - psychology</topic><topic>Hallucinations - drug therapy</topic><topic>Hallucinations - physiopathology</topic><topic>Hallucinations - psychology</topic><topic>haloperidol</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>physostigmine</topic><topic>Physostigmine - therapeutic use</topic><topic>Receptors, Cholinergic - drug effects</topic><topic>Receptors, Cholinergic - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cummings, Jeffrey L.</creatorcontrib><creatorcontrib>Gorman, David G.</creatorcontrib><creatorcontrib>Shapira, Jill</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biological psychiatry (1969)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cummings, Jeffrey L.</au><au>Gorman, David G.</au><au>Shapira, Jill</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physostigmine ameliorates the delusions of Alzheimer's disease</atitle><jtitle>Biological psychiatry (1969)</jtitle><addtitle>Biol Psychiatry</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>33</volume><issue>7</issue><spage>536</spage><epage>541</epage><pages>536-541</pages><issn>0006-3223</issn><eissn>1873-2402</eissn><coden>BIPCBF</coden><abstract>Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a doubleblind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>8513039</pmid><doi>10.1016/0006-3223(93)90009-3</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-3223 |
| ispartof | Biological psychiatry (1969), 1993-04, Vol.33 (7), p.536-541 |
| issn | 0006-3223 1873-2402 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_75783532 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | acetylcholine acetylcholinesterase acetylcholinesterase inhibitor Aged Alzheimer Disease - drug therapy Alzheimer Disease - physiopathology Alzheimer Disease - psychology Alzheimer's disease Biological and medical sciences delusions Delusions - drug therapy Delusions - physiopathology Delusions - psychology Hallucinations - drug therapy Hallucinations - physiopathology Hallucinations - psychology haloperidol Humans Male Medical sciences Miscellaneous Neuropharmacology Pharmacology. Drug treatments physostigmine Physostigmine - therapeutic use Receptors, Cholinergic - drug effects Receptors, Cholinergic - physiology |
| title | Physostigmine ameliorates the delusions of Alzheimer's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A37%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physostigmine%20ameliorates%20the%20delusions%20of%20Alzheimer's%20disease&rft.jtitle=Biological%20psychiatry%20(1969)&rft.au=Cummings,%20Jeffrey%20L.&rft.date=1993-04-01&rft.volume=33&rft.issue=7&rft.spage=536&rft.epage=541&rft.pages=536-541&rft.issn=0006-3223&rft.eissn=1873-2402&rft.coden=BIPCBF&rft_id=info:doi/10.1016/0006-3223(93)90009-3&rft_dat=%3Cproquest_cross%3E75783532%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75783532&rft_id=info:pmid/8513039&rft_els_id=0006322393900093&rfr_iscdi=true |